Teriparatide inhalation - Nektar Therapeutics

Drug Profile

Teriparatide inhalation - Nektar Therapeutics

Alternative Names: Parathyroid hormone inhalation - Eli Lilly/Inhale Therapeutic Systems; PTH inhalation - Eli Lilly/Inhale Therapeutic Systems; Teriparatide inhalation - Eli Lilly/Inhale Therapeutic Systems

Latest Information Update: 12 Mar 2008

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Developer ALZA Corporation; Eli Lilly; Nektar Therapeutics
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 18 Feb 2003 Nektar Therapeutics is seeking a new partner for the development of teriparatide inhalation
  • 15 Jan 2003 Inhale Therapeutic Systems is now called Nektar Therapeutics
  • 27 Oct 2001 Suspended-I for Postmenopausal osteoporosis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top